Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ocugen Inc OCGN

Healthcare Biotechnology
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.


NDAQ:OCGN - Post by User

Ocugen Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by Richardson35on Dec 01, 2021 7:36pm
91 Views
Post# 34187820

📰📣iMining Technologies Launches Concierge Service📢📣📣

📰📣iMining Technologies Launches Concierge Service📢📣📣
↓↓↓↓↓↓↓↓↓↓↓↓↓Click the link for the Full Details of the Article: ↓↓↓↓↓↓↓↓↓↓↓↓↓
 
 
 
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - iMining Technologies Inc. (TSXV: IMIN) (the "Company" or "iMining") announced today that its wholly owned subsidiary, BitBit Financial Inc. ("BitBit") has launched a concierge service to support and guide High Net Worth Individuals, Institutions and Celebrities on their purchase of NFTs and other digital assets. NFTs are Non-Fungible Tokens of digital collectibles including art, music, photos, videos, and other items.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities